Medication management for people with dementia in primary care: description of implementation in the DelpHi study

Thomas Fiß, Jochen René Thyrian, Diana Wucherer, Grit Aßmann, Ingo Kilimann, Stefan J Teipel, Wolfgang Hoffmann, Thomas Fiß, Jochen René Thyrian, Diana Wucherer, Grit Aßmann, Ingo Kilimann, Stefan J Teipel, Wolfgang Hoffmann

Abstract

Background: As the population ages, the relative and absolute number of age-associated diseases such as dementia will increase. Evaluation of the suitability and intake of medication and pharmacological treatment is an important aspect of care for people with dementia, especially if they live at home. Regular medication reviews and systematic cooperation between physicians and pharmacists are not common in routine care. Medication management (MM), based on such a comprehensive home medication review could help to reduce drug-related problems and costs. The present article presents a medication management specifically for the application in the ambulatory setting and describes its implementation as part of a larger trial.

Methods/design: A home medication review (HMR) and MM is implemented as part of the DelpHi study, a population based prospective, cluster-randomized controlled intervention study to test the efficacy and efficiency of the implementation of a collaborative care model in primary care.

Participants: people with dementia (PWD) and their caregivers are recruited by the patient's general practitioner. Inclusion criteria are a positive screening result for dementia, living at home and regular intake of drugs. PWD are asked to specify their regular pharmacy which is asked to participate in the study, too.

Intervention: a comprehensive HMR is conducted as computer-assisted personal interview by specifically qualified Dementia Care Manager (DCM) at the people's home. It includes detailed information about drugs taken, their storage, administration, adherence and adverse events. The MM is conducted in cooperation between DCM, pharmacist and general practitioner and consists of a pharmaceutical evaluation, pharmaceutical recommendations and their application. Pharmacists are trained and provided with regularly updated information. The MM is designed to give information and recommendations concerning antidementia drugs, occurrence of drug related problems, intake of anticholinergic drugs, potentially clinically relevant drug-drug-interactions, adverse drug events and medication adherence.

Discussion: The DelpHi-approach for medication management employs comprehensive instruments and procedures in the primary care setting under routine care conditions, and this approach should be useful in improving pharmacotherapy as part of the comprehensive treatment and care for people with dementia.

Trial registration: The trial is registered at ClinicalTrials.gov, number NCT01401582.

Figures

Figure 1
Figure 1
Recommendation for a workflow of the medication management for patients with dementia.

References

    1. Siewert U, Fendrich K, Doblhammer-Reiter G, Scholz RD, Schuff-Werner P, Hoffmann W. Health care consequences of demographic changes in Mecklenburg-West Pomerania: projected case numbers for age-related diseases up to the year 2020, based on the study of health in Pomerania (SHIP) Dtsch Arztebl Int. 2010;107:328–334.
    1. Thyrian JR, Dreier A, Fendrich K, Lueke S, Hoffmann W. Demenzerkrankungen–Wirksame Konzepte gesucht. Deutsches Ärzteblatt. 2011;108:A1954–A1956.
    1. National Institute for Health and Clinical Excellence. NICE clinical guideline. 42. NICE; 2006. (Dementia supporting people with dementia and their carers in health and social care). .
    1. Campbell N, Boustani M, Limbil T, Ott C, Fox C, Maidment I. et al.The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging. 2009;4:225–233.
    1. Fortin MP, Rouch I, Dauphinot V, Gedeon C, Genthon S, Bonnefoy M. et al.Effects of anticholinergic drugs on verbal episodic memory function in the elderly: a retrospective, cross-sectional study. Drugs Aging. 2011;28:195–204. doi: 10.2165/11586580-000000000-00000.
    1. Sela-Katz P, Rabinowitz I, Shugaev I, Shigorina G. Basic knowledge of the medication regimen correlates with performance on cognitive function tests and diagnosis of dementia in elderly patients referred to a geriatric assessment unit. Gerontology. 2010;56:491–495. doi: 10.1159/000304738.
    1. Rottenkolber D, Schmiedl S, Rottenkolber M, Farker K, Salje K, Mueller S. et al.Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations. Pharmacoepidemiol Drug Saf. 2011;20:626–634. doi: 10.1002/pds.2118.
    1. Schneeweiss S, Hasford J, Gottler M, Hoffmann A, Riethling AK, Avorn J. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol. 2002;58:285–291. doi: 10.1007/s00228-002-0467-0.
    1. Schaefer M. Discussing basic principles for a coding system of drug-related problems: the case of PI-Doc. Pharm World Sci. 2002;24:120–127. doi: 10.1023/A:1019543029936.
    1. Cancelli I, Beltrame M, Gigli GL, Valente M. Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patients. Neurol Sci. 2009;30:87–92. doi: 10.1007/s10072-009-0033-y.
    1. Cancelli I, Beltrame M, D’Anna L, Gigli GL, Valente M. Drugs with anticholinergic properties: a potential risk factor for psychosis onset in Alzheimer’s disease? Expert Opin Drug Saf. 2009;8:549–557. doi: 10.1517/14740330903099636.
    1. Carriere I, Fourrier-Reglat A, Dartigues JF, Rouaud O, Pasquier F, Ritchie K. et al.Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med. 2009;169:1317–1324. doi: 10.1001/archinternmed.2009.229.
    1. Giron MS, Wang HX, Bernsten C, Thorslund M, Winblad B, Fastbom J. The appropriateness of drug use in an older nondemented and demented population. J Am Geriatr Soc. 2001;49:277–283. doi: 10.1046/j.1532-5415.2001.4930277.x.
    1. van der Velde N, Stricker BH, Pols HA, van der Cammen TJ. Risk of falls after withdrawal of fall-risk-increasing drugs: a prospective cohort study. Br J Clin Pharmacol. 2007;63:232–237. doi: 10.1111/j.1365-2125.2006.02736.x.
    1. Hoffmann W, van den Berg N, Thyrian JR, Fiss T. Frequency and determinants of potential drug-drug interactions in an elderly population receiving regular home visits by GPs–results of the home medication review in the AGnES-studies. Pharmacoepidemiol Drug Saf. 2011;20(12):1311–1318. doi: 10.1002/pds.2224.
    1. Arlt S, Lindner R, Rosler A, Von Renteln-Kruse W. Adherence to medication in patients with dementia: predictors and strategies for improvement. Drugs Aging. 2008;25:1033–1047. doi: 10.2165/0002512-200825120-00005.
    1. Jackson SH, Jansen PA, Mangoni AA. Off-label prescribing in older patients. Drugs Aging. 2012;29:427–434. doi: 10.2165/11633520-000000000-00000.
    1. Holland R, Lenaghan E, Harvey I, Smith R, Shepstone L, Lipp A. et al.Does home based medication review keep older people out of hospital? The HOMER randomised controlled trial. BMJ. 2005;330:293. doi: 10.1136/.
    1. Holland R, Smith R, Harvey I. Where now for pharmacist led medication review? J Epidemiol Community Health. 2006;60:92–93. doi: 10.1136/jech.2005.035188.
    1. Holland R, Desborough J, Goodyer L, Hall S, Wright D, Loke YK. Does pharmacist-led medication review help to reduce hospital admissions and deaths in older people? A systematic review and meta-analysis. Br J Clin Pharmacol. 2008;65:303–316. doi: 10.1111/j.1365-2125.2007.03071.x.
    1. Schaefer M, Schulz M, Emmermann A, Mühlbauer K, Verheyen F. Manuale zur Pharmazeutischen Betreuung-Band 1: Grundlagen der Pharmazeutischen Betreuung [manual fo pharmaceutical care: part I: basics] ABDA-Bundesvereinigung Deutscher Apotheker GOVI-Verlag Eschborn; 2000.
    1. Fiss T. Erfassung und Lösung arzneimittelbezogener Probleme in einer Kohorte älterer, multimorbider Hausbesuchspatienten. Hamburg: Verlag Dr. Kovac GmbH; 2011. Eschborn preceding to the year 2000.
    1. Maidment ID, Fox C, Boustani M, Katona C. Medication management-the missing link in dementia interventions. Circulation. 2006;114(13):1432–1445. doi: 10.1161/CIRCULATIONAHA.106.177322.
    1. Krumholz HM, Currie PM, Riegel B, Phillips CO, Peterson ED, Smith R. et al.A taxonomy for disease management: a scientific statement from the American Heart Association Disease Management Taxonomy Writing Group. Circulation. 2006;114:1432–1445. doi: 10.1161/CIRCULATIONAHA.106.177322.
    1. Eickhoff C, Schulz M. Pharmaceutical care in community pharmacies: practice and research in Germany. Ann Pharmacother. 2006;40:729–735. doi: 10.1345/aph.1G458.
    1. Karopka T, Bruder I, van den Berg N, Hoffmann W, Heuer A. ICT architecture for a community medicine nurse project. Healthinf 2008: Proc First Int Conf Health Inform. 2008;2:26–30.
    1. Thyrian JR, Fiss T, Dreier A, Bowing G, Angelow A, Lueke S. et al.Life-and person-centred help in Mecklenburg-Western Pomerania, Germany (DelpHi): study protocol for a randomised controlled trial. Trials. 2012;13:56. doi: 10.1186/1745-6215-13-56.
    1. Kalbe E, Kessler J, Calabrese P, Smith R, Passmore AP, Brand M. et al.DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriatr Psychiatry. 2004;19:136–143. doi: 10.1002/gps.1042.
    1. Dreier A, Thyrian JR, Hoffmann W. Dementia care manager in der ambulanten Demenzversorgung: Entwicklung einer innovativen Qualifizierung für Pflegefachkräfte. Pflege&Gesellschaft. 2011;16:53–64.
    1. Sandholzer H, Hellenbrand W, Renteln-Kruse W, Van WC, Walker P. STEP–standardized assessment of elderly people in primary care. Dtsch Med Wochenschr. 2004;129(Suppl 4):S183–S226.
    1. Zaudig M. A new systematic method of measurement and diagnosis of “mild cognitive impairment” and dementia according to ICD-10 and DSM-III-R criteria. Int Psychogeriatr. 1992;4(Suppl 2):203–219.
    1. Fiss T, Ritter CA, Alte D, van den Berg N, Hoffmann W. Detection of drug related problems in an interdisciplinary health care model for rural areas in Germany. Pharm World Sci. 2010;32:566–576. doi: 10.1007/s11096-010-9409-6.
    1. de KE, Van der HD, Landewe R, Van der TH, Van der LS. The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study. J Rheumatol. 2003;30:2469–2475.
    1. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74. doi: 10.1097/00005650-198601000-00007.
    1. Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42:241–247. doi: 10.1016/S0920-9964(99)00130-9.
    1. Jank S, Bertsche T, Schellberg D, Herzog W, Haefeli WE. The A14-scale: development and evaluation of a questionnaire for assessment of adherence and individual barriers. Pharm World Sci. 2009;31(4):426–431. doi: 10.1007/s11096-009-9296-x.
    1. Meyer J, Ostrzinski S, Fredrich D, Havemann C, Krafczyk J, Hoffmann W. Efficient data management in a large-scale epidemiology research project. Comput Methods Programs Biomed. 2012;107:425–435. doi: 10.1016/j.cmpb.2010.12.016.
    1. Hansten PD, Horn JR, Hazlet TK. ORCA: OpeRational classificAtion of drug interactions. J Am Pharm Assoc (Wash ) 2001;41:161–165.
    1. Vonbach P, Dubied A, Krahenbuhl S, Beer JH. Evaluation of frequently used drug interaction screening programs. Pharm World Sci. 2008;30:367–374. doi: 10.1007/s11096-008-9191-x.
    1. ABDATA Pharma-Daten Service. ABDA-Datenbank [ABDA database] 2010. .
    1. Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med. 1991;151:1825–1832. doi: 10.1001/archinte.1991.00400090107019.
    1. Chien WT, Lee IY. Randomized controlled trial of a dementia care programme for families of home-resided older people with dementia. J Adv Nurs. 2010;67(4):774–87.
    1. Zuckerman IH, Hernandez JJ, Gruber-Baldini AL, Hebel JR, Stuart B, Zimmerman S, Magaziner J. Potentially inappropriate prescribing before and after nursing home admission among patients with and without dementia. Am J Geriatr Pharmacother. 2005;3:246–254. doi: 10.1016/j.amjopharm.2005.12.007.
    1. Geurts MM, Talsma J, Brouwers JR, De Gier JJ. Medication review and reconciliation with cooperation between pharmacist and general practitioner and the benefit for the patient: a systematic review. Br J Clin Pharmacol. 2012.
    1. Topinkova E, Baeyens JP, Michel JP, Lang PO. Evidence-based strategies for the optimization of pharmacotherapy in older people. Drugs Aging. 2012;29:477–494. doi: 10.2165/11632400-000000000-00000.
    1. Schaefer M. Systematic drug documentation. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2005;48:736–741. doi: 10.1007/s00103-005-1072-z.
    1. Spinewine A, Fialova D, Byrne S. The role of the pharmacist in optimizing pharmacotherapy in older people. Drugs Aging. 2012;29:495–510. doi: 10.2165/11631720-000000000-00000.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren